Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 MNX Global Logistics, Medical ... renewed a multi-year contract providing time- and mission-critical ... spinal device company in the world. The precision ... is well suited to MNX,s main business competencies. ... involves a surgeon, surgical team and patient, who ...
(Date:8/26/2014)... , Aug. 26, 2014   Tocagen Inc. ... been named vice president, clinical development, and Mary ... operations. "As we advance Toca 511 ... expanding our clinical team with individuals who have deep ... activities," said Jamey Skillings , M.D., Chief Medical ...
(Date:8/26/2014)... , Aug. 26, 2014 Profil Institute ... organization (CRO) focused on diabetes and obesity, announced today a ... of more than 200 phase I – IIa clinical ... treatment of type 1 and type 2 diabetes.   ... research is what it represents for the public domain," ...
Breaking Medicine Technology:MNX Global Logistics renews multi-year contract with NuVasive, Inc. 2Tocagen Expands Clinical Development Team; 2Tocagen Expands Clinical Development Team; 3Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 3
... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:8/27/2014)... ALS Insights is a dedicated website created by ... a series of compelling interviews with people who have ... in searing honesty, about issues such as acceptance vs. ... happened in the final days and how the families ... dramatic increase in public awareness and financial support for ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 ... cyclists of all abilities to go the distance this ... Alex’s Million Mile – Run. Walk. Ride. initiative, hosted ... and increase awareness of childhood cancer. September represents ... year’s Alex’s Million Mile, Inspira Marketing Group has teamed ...
(Date:8/27/2014)... Washington, D.C. (PRWEB) August 27, 2014 ... of Neurosurgery discusses the importance of time in correcting ... study focuses on a variety of anticoagulants and examines ... , According to the research, although anticoagulants have been ... stroke and systemic embolism, they are also known to ...
(Date:8/27/2014)... August 27, 2014 In My Solitude, a ... Collection” to provide a growing number of women from college ... for goal setting and relaxing at the same time. , ... uses scent memory and visualization to help women stay focused ... each time they light a candle and enjoy the fragrance. ...
(Date:8/27/2014)... 27, 2014 Janice Holly Booth ... when no-one would join her on an adventure outing to ... extreme sport involving ropes, harnesses and rappelling into mysterious, dark ... solo travel but definitely not my last,” she says. “I ... pushed me to the edge, and experienced first-hand the kind ...
Breaking Medicine News(10 mins):Health News:ALS Insights Launched as Web Resource of Interviews and Information 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 3Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Best-selling Author Janice Holly Booth Offers Tips to Navigating Fear and Living a Fuller Life 2
... WEST LAFAYETTE, Ind. - A Purdue University research team ... antimicrobial agent as needed for extending the shelf life ... Yuan Yao, an assistant professor of food science, altered ... called phytoglycogen, which led to the creation of several ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... birth had a higher risk of behavior problems by their ... the devices, a new study of nearly 29,000 children suggests. ... of 13,000 children conducted by the same U.S. researchers. And ...
... too early are at an increased risk of death, ... Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100349.pdf ... that describes the flow rate of fluid going through ... Current guidelines in the United States place more emphasis ...
... (LSHTM) has contributed to a study showing that a low ... The study is published in today,s Lancet . ... Peter Rothwell in Oxford, and is based on an overview ... concerned with reducing heart attacks, but have also gathered information ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... to sex, according to an Australian study. The researchers found ... at least once a year -- including about 1 in 10 ... who are sexually active say they,d love to be having more ...
... the American Society of Hematology (ASH) annual meeting, investigators at ... why chronic lymphocytic leukemia (CLL) tends to recur in the ... bloodstream by chemotherapy. Their findings will be reported during in ... in room 315 of the Orange County Convention Center. ...
Cached Medicine News:Health News:Nanoparticle gives antimicrobial ability to fight Listeria longer 2Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 2Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 3Health News:Could Cell Phones Raise Odds for Behavioral Woes in Kids? 4Health News:Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent 2Health News:Many Men Over 75 Still Sexually Active: Study 2Health News:Many Men Over 75 Still Sexually Active: Study 3Health News:Study identifies drug resistance of CLL in bone marrow and lymph nodes 2
Simple straight stem design for the low-demand patient....
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
The P.S.L. stem is manufactured from cobalt chrome and is available with or without porous coating to give the surgeon the option of utilizing either the cementless of cemented technique at his or he...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: